Patents Assigned to Duke University
  • Patent number: 12290603
    Abstract: The present disclosure provides, in part, peptide self-assemblies that are made into tablet form and methods of making and using the same. In some embodiments, the disclosure provides methods and formulations for a tabletized form of a vaccine, particularly a vaccine comprising self-assembling peptide-polymer nanofibers, an excipient and an adjuvant. Methods of making and using the tablet formulation are also provided.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: May 6, 2025
    Assignee: Duke University
    Inventors: Joel Collier, Sean Kelly
  • Patent number: 12290549
    Abstract: The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: May 6, 2025
    Assignee: Duke University
    Inventors: Priya S. Kishnani, Suhrad G. Banugaria, Dwight D. Koeberl, Sean N. Prater
  • Patent number: 12288132
    Abstract: Aspects of the present disclosure describe techniques that involve an active stabilization of coherent controllers using nearby qubits. In an aspect, a quantum information processing (QIP) system for stabilizing phase damping in qubits is described that provides a first and a second qubit ion, measuring magnetic field fluctuations using the second qubit ion, and generates one or more magnetic fields based on the measured magnetic field fluctuations, the one or more magnetic fields being applied near the first qubit ion to cancel the magnetic field fluctuations to stabilize the phase damping of the first qubit ion. Another such QIP system performs provides a first and a second qubit ion, locks a local oscillator to a frequency reference associated with the second qubit ion, and tracks, using the local oscillator, a frequency of the first qubit ion based on the frequency reference. Methods associated with these QIP systems are also described.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: April 29, 2025
    Assignees: University of Maryland, College Park, Duke University
    Inventors: Jungsang Kim, Kenneth Brown, Christopher Monroe
  • Patent number: 12288158
    Abstract: The present disclosure describes a computational imaging system that uses a supervised learning algorithm to jointly process the captured image data to identify task-optimal hardware settings and then uses the task-optimal hardware settings to dynamically adjust its hardware to improve specific performance. The primary application of this device is for rapid and accurate automatic analysis of images of biological specimens.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: April 29, 2025
    Assignee: Duke University
    Inventors: Pratik Bokadia, Amey Chaware, Roarke Horstmeyer, Kanghyun Kim, Pavan Konda
  • Patent number: 12286471
    Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.
    Type: Grant
    Filed: January 3, 2024
    Date of Patent: April 29, 2025
    Assignee: Duke University
    Inventors: Edward F. Patz, Jr., Michael J. Campa, Elizabeth Gottlin, Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody
  • Patent number: 12285444
    Abstract: The invention provides a method of promoting reprogramming of a cardiac fibroblast into a cardiomyocyte by contacting the cardiac fibroblast with an isolated polynucleotide molecule comprising at least two functional miRNA sequences using a multicistronic expression system for reprogramming of fibroblasts into functional mature cardiomyocytes.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: April 29, 2025
    Assignee: Duke University
    Inventors: Conrad P. Hodgkinson, Victor J. Dzau
  • Patent number: 12281862
    Abstract: A dual-mode heating and cooling system includes a dual-mode heating and cooling device including a cooling part and a heating part that are configured to be selectively exposed to sunlight in a cooling mode and a heating mode, respectively, with the cooling part configured to provide radiative cooling to a structure, and with the heating part configured to provide solar heating to the structure. The device may include a film with the cooling part and the heating part side-by-side on the film.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: April 22, 2025
    Assignee: Duke University
    Inventors: Pochun Hsu, Xiuqiang Li
  • Patent number: 12275986
    Abstract: Provided herein are methods for treating cancer in a subject comprising administering an ICB therapy to a subject having cancer, wherein the subject's cancer comprises one or more mutations in two or more genes associated with responsiveness to immune checkpoint blockade (ICB).
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: April 15, 2025
    Assignee: Duke University
    Inventors: Chuan-Yuan Li, Dong Pan
  • Publication number: 20250114350
    Abstract: The invention provides competitive inhibitors of farnesyl transferase, compositions comprising the competitive inhibitors of farnesyl transferase, and their use as antifungal agents and as agents for the prevention of the formation or growth of biofilms.
    Type: Application
    Filed: October 4, 2024
    Publication date: April 10, 2025
    Applicants: Regents of the University of Minnesota, Duke University
    Inventors: Mark Dewey Distefano, Feng Xu, Lorena S. Beese, Homme W. Hellinga, You Wang, Andrew A. Alspaugh
  • Patent number: 12263142
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Grant
    Filed: August 29, 2023
    Date of Patent: April 1, 2025
    Assignee: Duke University
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • Patent number: 12257308
    Abstract: Described herein are thermally responsive polymer-therapeutic molecule conjugates comprising a therapeutic molecule conjugated to a thermally responsive polymer with an acrylate, methacrylate, acrylamide, and/or methacrylamide backbone and a plurality of oligoethylene glycol side chains.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: March 25, 2025
    Assignee: Duke University
    Inventors: Ashutosh Chilkoti, Imran Ozer
  • Patent number: 12252750
    Abstract: The invention disclosed herein relates generally to the fields of microbiology, ecology and microfluidics. Particularly, the invention disclosed herein provides compositions and methods for isolating bacteria from complex microbial communities and measuring growth rates of the isolated bacteria in a given environmental condition.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: March 18, 2025
    Assignee: Duke University
    Inventors: Lawrence David, Rachael Bloom
  • Patent number: 12247090
    Abstract: The present disclosure describes, in part, an enzyme-mediated radical initiating system and methods of using the system to produce polymers, including polymeric hydrogels, at ambient conditions.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: March 11, 2025
    Assignee: Duke University
    Inventors: Teng Su, Jennifer West, Neica Joseph
  • Patent number: 12246179
    Abstract: Systems and methods for stimulation of neurological tissue generate stimulation trains with temporal patterns of stimulation, in which the interval between electrical pulses (the inter-pulse intervals) changes or varies over time. Compared to conventional continuous, high rate pulse trains having regular (i.e., constant) inter-pulse intervals, the non-regular (i.e., not constant) pulse patterns or trains that embody features of the invention provide a lower average frequency.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: March 11, 2025
    Assignee: Duke University
    Inventors: Warren M. Grill, Jr., Alan D. Dorval, II, Robert Strother
  • Patent number: 12247977
    Abstract: The present disclosure provides methods for determining the presence or absence of and/or the etiology of an acute respiratory viral infection in a subject, as well as methods of treating the subject based on the determination, by measuring on a platform the expression levels of a pre-defined set of gene products.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 11, 2025
    Assignee: Duke University
    Inventors: Thomas W. Burke, Ricardo Henao Giraldo, Erik Soderblom, Joseph Lucas, Christopher W. Woods, Geoffrey S. Ginsburg
  • Patent number: 12237162
    Abstract: Aspects of the present disclosure describe systems, methods, and structures that enable a compact, UHV ion trap system that can operate at temperatures above cryogenic temperatures. Ion trap systems in accordance with the present disclosure are surface treated and sealed while held in a UHV environment, where disparate components are joined via UHV seals, such as weld joints, compressible metal flanges, and UHV-compatible solder joints. As a result, no cryogenic pump is required, thereby enabling an extremely small-volume system.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: February 25, 2025
    Assignees: Duke University, ColdQuanta, Inc.
    Inventors: Jungsang Kim, Geert Vrijsen, Ismail Inlek, Tom Noel, Megan Ivory, Alexander Kato, Steve Hughes
  • Patent number: 12233137
    Abstract: Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
    Type: Grant
    Filed: August 11, 2023
    Date of Patent: February 25, 2025
    Assignees: The Johns Hopkins University, Duke University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Vivek Kumar, Sangeeta Ray, Michael Zalutsky, Ganesan Vaidyanathan
  • Patent number: 12220451
    Abstract: Methods of generating an autologous cellular vaccine comprising monocytes or neutrophils and an antigenic polypeptide or nucleotide encoding the antigenic polypeptide are provided. The antigen-loaded cell-based vaccine compositions made using these methods are also provided. Methods of using the antigen-loaded cell-based vaccine compositions are also provided and these vaccines may be used to treat cancer. Kits for carrying out the methods described herein are also provided.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: February 11, 2025
    Assignee: Duke University
    Inventors: Michael D. Gunn, Min-Nung Huang
  • Patent number: 12221447
    Abstract: The presently disclosed subject matter is directed to compositions and methods for treating CaMKK2-mediated ophthalmic diseases, including but not limited to 1) ocular surface inflammatory diseases (OSIDs), including but not limited to ocular graft versus host disease, ocular cicatricial pemphigoid, vernal keratoconjunctivitis, allergic eye disease, meibomian gland dysfunction, aqueous tear deficiency (common dry eye disease), corneal scarring, and conjunctival scarring and fibrosis; 2) uveitis and other inflammatory diseases of the eye, including but not limited to keratitis, scleritis, iritis, iridocyclitis, intermediate uveitis, pars planitis, posterior uveitis, choroiditis, chorioretinitis, retinitis, or panuveitis of noninfectious, infectious, or idiopathic etiologies; and 3) “back of the eye” retinal diseases, which include dry age-related macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular diseases (e.g.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: February 11, 2025
    Assignee: Duke University
    Inventors: Scott W. Cousins, Priyatham S. Mettu, David M. Gooden
  • Patent number: 12214054
    Abstract: Disclosed herein are therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: February 4, 2025
    Assignee: Duke University
    Inventors: Charles A. Gersbach, Jacqueline N. Robinson-Hamm